Suzhou Suncadia Biopharmaceuticals Co., Ltd.

This study tests a new drug called SHR-A1811 combined with standard chemotherapy (carboplatin and bevacizumab) in 150 women whose ovarian cancer has returned after initial platinum-based treatment. The goal is to find the safest dose and see if the combination shrinks tumors or s…

This early-stage study tests an experimental drug called SHR-3821 in 162 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps control the cancer. Participants receive…

This study tests whether combining the immunotherapy drug adebrelimab with other targeted drugs and chemotherapy can shrink stomach or gastroesophageal junction tumors. About 200 adults who have not had prior treatment for their cancer will receive one of several drug combination…

This study tests whether adding a new drug (SHR-8068) to standard immunotherapy and chemotherapy can help people with advanced bile duct cancer live longer. About 604 adults who have not had prior treatment will be randomly assigned to receive either the new combination or anothe…

This study tests a new drug called SHR-8068 combined with other cancer treatments for people with colorectal cancer. The goal is to see if the combination is safe and effective at shrinking tumors or slowing cancer growth. About 200 adults aged 18 to 75 with good performance stat…

This phase 3 study tests whether adding SHR-A2009 to aumolertinib works better than aumolertinib alone for people with advanced EGFR-mutant non-small cell lung cancer who haven't had treatment yet. About 576 adults aged 18-75 will join. The main goal is to see if the combo delays…

This study tests whether a new combination of two drugs (SHR-A1811 and SHR-1316) works better than the current standard treatment for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. About 400 women aged 18-75 with cancer that …

This study tests a new drug called SHR-4849 combined with other cancer medicines in people with advanced solid tumors. The goal is to see if the combination is safe and can shrink tumors. About 120 adults aged 18 to 75 with measurable tumors and adequate organ function will parti…

This study tests a new drug called SHR-9839 combined with other anti-tumor treatments for people with advanced solid tumors. The goal is to see if the combination is safe and helps shrink or control tumors. About 70 adults aged 18-70 with measurable tumors and good performance st…

This early-phase study tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The main goals are to find a safe dose and check for side effects. About 138 adults with the disease will take part to see how the drug works in the body and if it he…

This study tests whether adding two experimental drugs (adebrelimab and SHR-8068) to standard chemoradiation helps shrink locally advanced rectal cancer before surgery. About 165 adults aged 18-75 with resectable tumors who haven't had prior treatment will participate. The main g…

This study tests whether a new drug combination (SHR-8068 plus adebrelimab and chemotherapy) works better than the current standard (tislelizumab plus chemotherapy) for people with advanced or metastatic non-small cell lung cancer who have not had prior treatment. About 460 adult…

This early-phase study tests a new drug (SHR-2524) combined with bevacizumab in 36 adults with advanced liver cancer that cannot be removed by surgery. Participants have not had prior cancer treatment. The main goals are to check safety and how the drugs move through the body. Th…

This study compares a new combination of two drugs (SHR-A2102 and adebrelimab) against standard chemotherapy for people with advanced bladder cancer that has spread and hasn't been treated before. About 462 adults aged 18 to 80 will take part. The goal is to see if the new combo …

This study tests a new three-drug combination (SHR-8068, adebrelimab, and bevacizumab) against standard two-drug treatments for advanced liver cancer that cannot be removed by surgery. About 590 adults with this type of cancer will participate. The goal is to see if the new combo…

This early-stage study tests a new drug called SHR-7782 in 200 people with advanced cancer that has spread or cannot be removed. The main goals are to find the safest dose and see if the drug can shrink tumors. Participants must have measurable tumors and be healthy enough for tr…

This study tests an experimental drug called SHR-1681 in about 300 adults whose advanced solid tumors have not responded to standard treatments. The main goals are to find the safest dose and to check for side effects. Researchers will also measure how the drug moves through the …

This study tests a new combination of drugs (SHR-A1811, chemotherapy, and adebrelimab) against the standard treatment for advanced stomach or gastroesophageal junction cancer that hasn't been treated before. About 600 adults aged 18-75 with measurable tumors will be randomly assi…

This study tests whether adding the experimental drug SHR-A1912 to standard chemotherapy (R-GEMOX) works better than chemotherapy alone for people whose diffuse large B-cell lymphoma has come back or not responded to treatment. About 280 adults aged 18–79 will take part. The main…

This study tests a combination of three drugs (SHR-8068, adebrelimab, and others) in 139 adults with advanced kidney cancer that cannot be removed by surgery or has spread. The goal is to see if the treatment can shrink tumors and control the disease. Participants must provide a …

This study tests a new drug, SHR-A1904, in people with advanced bile duct cancer that has not responded to previous treatments. The drug targets a specific protein (CLDN18.2) on cancer cells. About 151 participants will receive the drug to see if it can shrink tumors or slow dise…

This study tests an experimental drug called SHR-2017 in 210 adults with solid tumors that have spread to the bones. The goal is to see if it can reduce pain and prevent bone problems like fractures or the need for radiation or surgery. Participants will receive either SHR-2017 o…

This early-phase study tests an injectable drug called SHR-A1811(sc) in 107 adults with solid tumors. The goal is to see how the drug moves through the body, check its safety, and look for signs it shrinks tumors. Participants must have advanced cancer and be in fairly good healt…

This study tests a new drug called SHR-4375 combined with other cancer treatments in 198 adults with advanced solid tumors that have not responded to standard care. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth. Participants must…

This study tests a new drug called SHR-A1811 combined with chemotherapy and/or immunotherapy for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if the combination is safe and shrinks tumors. About 258 adults aged 18-75 who have …

This study tests a new drug called SHR-1826 combined with other cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 876 ad…

This study tests a new drug called SHR-A2102 against standard chemotherapy in people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemo and immunotherapy. About 398 participants will be randomly assigned to receive either SHR-A2102 or a do…

This early-stage study tests a new drug called SHR-1894 in 40 healthy adults to see if it is safe and how the body processes it. Participants receive a single injection and are monitored for side effects and drug levels. The goal is to gather safety information, not to treat any …